Download PDF
Exp Clin Endocrinol Diabetes 2007; 115(3): 175-178
DOI: 10.1055/s-2007-970411
Review Article

© J. A. Barth Verlag in Georg Thieme Verlag KG · Stuttgart · New York

Insights into the Molecular Biology of Adrenocortical Tumors

L. Groussin 1 , J. Bertherat 1 , C. Gicquel 1 , Y. le Bouc 1 , X. Bertagna 1
  • 1Clinique des Maladies Endocriniennes et Métaboliques, and Endocrinology Department, Institut Cochin Faculté de Médecine René and Laboratoire d'Explorations Fonctionnelles Trousseau, and the COMETE network, Paris, France
Further Information

Publication History

received 15. 8. 2005 first decision 27. 11. 2006

accepted 22. 1. 2007

Publication Date:
11 April 2007 (online)

Also available at
    Permissions and Reprints

Introduction

Adrenocortical tumors are rare tumors which can cause morbidity secondary to hypersecretion (i. e. Cushing's syndrome in adrenocortical adenoma or carcinoma, mineralocorticoid excess in Conn's adenoma) or to their oncogenic growth and metastases.

In the recent years progress has been made in our understanding of the pathophysiology of these endocrine tumors ([Latronico and Chrousos, 1997]; [Bornstein et al., 1999]; [Reincke et al., 2000]; [Bertherat et al., 2002]). Some molecular mechanisms of hormone hypersecretion or growth of adrenocortical tumors have been unraveled this last decade and offer new support to our understanding of adrenocortical tumor development. In particular, studies of familial forms of adrenocortical tumors have given us new insight in the genetics of these tumors. Some of these advances have already lead to new therapeutical or diagnostic approaches.

We will not provide here an extensive review of all studies that have been performed in adrenocortical tumors; we will rather focus on some aspects that are thought to be of major interest.

References

  • 1 Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma.  Clin Endocrinol. 2004;  60 273-287
    CrossrefPubMedGoogle Scholar
  • 2 Bertherat J. Protein kinase A in Carney Complex: a new example of cAMP pathway alteration in endocrine tumors.  Eur J Endocrinol. 2001;  144 209-211
    CrossrefPubMedGoogle Scholar
  • 3 Bertherat J, Gicquel C, Le Bouc Y, Bertagna X. Molecular genetics of adrenal tumours. In: John AH Wass and Stephen M Shalet, (eds) Oxford textbook of Endocrinology and Diabetes. Oxford: Oxford University Press 2002: 831-842
    Google Scholar
  • 4 Bertherat J, Groussin L, Sandrini F, Matyakhina L, Bei T, Stergiopoulos S, Papageorgiou T, Bourdeau I, Kirschner LS, Vincent-Dejean C, Perlemoine K, Gicquel C, Bertagna X, Stratakis CA. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity.  Cancer Res. 2003;  63 5308-5319
    PubMedGoogle Scholar
  • 5 Bertherat J, Contesse V, Louiset E, Barrande G, Duparc C, Groussin L, Emy P, Bertagna X, Kuhn JM, Vaudry H, Lefebvre H. In vivo and in vitro screening for illegitimate receptors in AIMAH causing Cushing's syndrome: identification of two cases of gonadotropin/GIP-dependent hypercortisolism.  J Clin Endocrinol Metab. 2005;  90 1302-1310
    CrossrefPubMedGoogle Scholar
  • 6 Beuschlein F, Reincke M, Karl M, Travis WD, Jaursch-Hancke C, Abdelhamid S, Chrousos GP, Allolio B. Clonal composition of human adrenocortical neoplasms.  Cancer Res. 1994;  54 4927-4932
    PubMedGoogle Scholar
  • 7 Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: recent advances in basic concepts and clinical management.  Ann Intern Med. 1999;  130 759-771
    PubMedGoogle Scholar
  • 8 Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity.  Medicine (Baltimore). 1985;  64 270-283
    CrossrefPubMedGoogle Scholar
  • 9 De Fraipont F, El Atifi M, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E, Berger F, Gicquel C, Chabre O, Feige JJ. Gene expression profiling of human adrenocortical tumors using complementary cDNA micro-arrays identifies several candidate genes as markers of malignancy.  J Clin Endocrinol Metab. 2005;  90 1819-1829
    PubMedGoogle Scholar
  • 10 Gicquel C, Leblond-Francillard M, Bertagna X, Louvel A, Chapuis Y, Luton JP, Girard F, Le Bouc Y. Clonal analysis of human adrenocortical carcinomas and secreting-adenomas.  Clin Endocrinol (Oxf). 1994;  40 465-477
    CrossrefPubMedGoogle Scholar
  • 11 Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, Schlumberger M, Louvel A, Luton JP, Le Bouc Y. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors. Study on a series of 82 tumors.  J Clin Endocrinol Metab. 1997;  87 2559-2565
    PubMedGoogle Scholar
  • 12 Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors.  Cancer Res. 2001;  61 6762-6767
    PubMedGoogle Scholar
  • 13 Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW, Taylor JM, Hanash SM. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis.  Am J Pathol. 2003;  162 521-531
    CrossrefPubMedGoogle Scholar
  • 14 Groussin L, Kirschner LS, Vincent-Dejean C, Perlemoine K, Jullian E, Delemer B, Zacharieva S, Pignatelli D, Carney JA, Luton JP, Bertagna X, Stratakis CA, Bertherat J. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD.  Am J Hum Genet. 2002;  71 1433-1442
    CrossrefPubMedGoogle Scholar
  • 15 Groussin L, Jullian E, Perlemoine K, Louvel A, Leheup B, Luton JP, Bertagna X, Bertherat J. Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease.  J Clin Endocrinol Metab. 2002;  87 4324-4329
    Google Scholar
  • 16 Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.  Nat Genet. 2000;  26 89-92
    Google Scholar
  • 17 Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex.  Hum Mol Genet. 2000;  9 3037-3046
    CrossrefPubMedGoogle Scholar
  • 18 Kjellman M, Roshani L, Teh BT, Kallioniemi OP, Hoog A, Gray S, Farnebo LO, Holst M, Backdahl M, Larsson C. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16.  J Clin Endocrinol Metab. 1999;  84 730-735
    CrossrefPubMedGoogle Scholar
  • 19 Lacroix A, Bolte E, Tremblay J, Dupre J, Poitras P, Fournier H, Garon J, Garrel D, Bayard F, Taillefer R. et al . Gastric inhibitory polypeptide-dependent cortisol hypersecretion-a new cause of Cushing's syndrome.  N Engl J Med. 1992;  327 974-980
    CrossrefPubMedGoogle Scholar
  • 20 Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome.  Endocrinol Rev. 2001;  22 75-110
    CrossrefPubMedGoogle Scholar
  • 21 Latronico AC, Chrousos G. Extensive personal experience: adrenocortical tumors.  J Clin Endocrinol Metab. 1997;  85 1317-1324
    PubMedGoogle Scholar
  • 22 Logié A, Boulle N, Gaston V, Perin L, Boudou P, Le Bouc Y, Gicquel C. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line.  J Mol Endocrinol. 1999;  23 23-32
    CrossrefPubMedGoogle Scholar
  • 23 Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, Bricaire H. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.  N Engl J Med. 1990;  322 1195-1201
    PubMedGoogle Scholar
  • 24 Pilon C, Pistorello M, Moscon A, Altavilla G, Pagotto U, Boscaro M, Fallo F. Inactivation of the p16 tumor suppressor gene in adrenocortical tumors.  J Clin Endocrinol Metab. 1999;  84 2776-2779
    CrossrefPubMedGoogle Scholar
  • 25 Reincke M, Beuschlein F, Slawik M, Borm K. Molecular adrenocortical tumourigenesis.  Eur J Clin Invest. 2000;  30 63-68
    CrossrefPubMedGoogle Scholar
  • 26 Reznik Y, Allali-Zerah V, Chayvialle A, Leroyer R, Leymarie P, Travert G, Lebrethon MC, Budi I, Balliere AM, Mahoudeau J. Food-dependent Cushing's syndrome mediated by aberrant adrenocortical sensitivity to gastric inhibitory polypeptide.  N Engl J Med. 1992;  327 981-986
    CrossrefPubMedGoogle Scholar
  • 27 Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.  N Engl J Med. 1991;  325 1688-1716
    Google Scholar

Correspondence

X. Bertagna

Clinique des Maladies

Endocriniennes et Métaboliques

Hôpital Cochin

27 rue du Fg-St-Jacques

75014 Paris

France

Phone: +33/1/58 41 17 90

Fax: +33/1/46 33 80 60

Email: xavier.bertagna@cch.aphp.fr

      >